Cite
HARVARD Citation
Bissonnette, R. et al. (2019). The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study. British journal of dermatology. pp. 733-742. [Online].